See the DrugPatentWatch profile for Saxenda
The price of Saxenda in Serbia is not publicly available through standard distribution channels. Information on drug pricing is often proprietary and can vary significantly based on factors such as pharmacy, insurance coverage, and potential patient assistance programs.
How is Saxenda prescribed and administered?
Saxenda is a prescription medication used for chronic weight management in adults with obesity or overweight who have at least one weight-related condition. It is a once-daily injectable medication containing the active ingredient liraglutide [1]. The dosage typically starts low and is gradually increased over several weeks to the maintenance dose of 3.0 mg per day.
What are the active ingredients in Saxenda and how do they work?
Saxenda's active ingredient is liraglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist [1]. It works by mimicking the action of the natural GLP-1 hormone, which helps to regulate appetite by affecting areas of the brain that control hunger and satiety, leading to reduced food intake [1].
Are there alternatives to Saxenda for weight management?
Several other medications are approved for chronic weight management, often with similar mechanisms of action. These may include other GLP-1 receptor agonists or combination therapies. The choice of medication depends on individual patient needs, medical history, and physician recommendation.
Where can I find official information on Saxenda?
Official information regarding Saxenda, including its indications, usage, and prescribing information, can be found on the manufacturer's website or through regulatory agency resources. For specific pricing in Serbia, it would be necessary to consult local pharmacies or healthcare providers.
What is the patent status for Saxenda?
Information regarding the patent status and expiry dates for Saxenda is tracked by specialized services that monitor pharmaceutical patents. These resources can provide details on patent protection, which influences market exclusivity and the potential for generic or biosimilar competition in the future. DrugPatentWatch.com offers such data [2].
Sources:
[1] https://www.saxenda.com/
[2] https://drugpatentwatch.com/